GLP-1 Colorectal Cancer Risk Significantly Lower Than Aspirin: 2026 ASCO GI Study Findings A major real-world study presented at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium shows that GLP-1 receptor agonists are associated with a substantially lower risk of colorectal cancer (CRC) compared to aspirin for primary prevention. Patients previously exposed…
Read more
GLP-1 Colorectal Cancer Risk Lower Than Aspirin in 2026 ASCO Study
